{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:56:46Z","timestamp":1790758606720,"version":"4.1.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.eururo.2012.09.033","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T03:38:39Z","timestamp":1348544319000},"page":"214-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":210,"title":["Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care"],"prefix":"10.1016","volume":"63","author":[{"given":"Osamu","family":"Ukimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"de la Taille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Giannarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stephen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2012.09.033_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.juro.2007.03.017","article-title":"Under diagnosis and over diagnosis of prostate cancer","volume":"178","author":"Graif","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0010","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.2005.11.148","article-title":"Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis","volume":"23","author":"Brenner","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jnci\/djq099","article-title":"Overdiagnosis in cancer","volume":"102","author":"Welch","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.09.033_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-5347(05)67995-5","article-title":"The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial","volume":"163","author":"Presti","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0022-5347(05)67993-1","article-title":"A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy","volume":"163","author":"Babaian","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0022-5347(05)66083-1","article-title":"Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies","volume":"166","author":"Stewart","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)64053-0","article-title":"Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy","volume":"169","author":"San Francisco","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-5347(05)64051-7","article-title":"Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study","volume":"169","author":"Presti","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0050","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.eururo.2007.08.006","article-title":"Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature","volume":"52","author":"Scattoni","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0055","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.eururo.2007.01.025","article-title":"Improved accuracy in predicting the presence of Gleason pattern 4\/5 prostate cancer by three-dimensional 26-core systematic biopsy","volume":"52","author":"Numao","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0060","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.eururo.2009.07.053","article-title":"The role of biopsy core number in selecting prostate cancer patients for active surveillance","volume":"56","author":"Ploussard","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0065","doi-asserted-by":"crossref","unstructured":"Ploussard G, Marchand C, Nicolaiew N, et al. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol. In press. http:\/\/dx.doi.org\/10.1016\/j.eururo.2012.05.049.","DOI":"10.1016\/j.eururo.2012.05.049"},{"key":"10.1016\/j.eururo.2012.09.033_bib0070","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.urology.2008.10.048","article-title":"Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer","volume":"73","author":"Capitanio","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.urology.2007.07.019","article-title":"Characteristics of prostate cancer detected by digital rectal examination only","volume":"70","author":"Okotie","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0080","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.09.033_bib0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2009.08.025","article-title":"A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer","volume":"57","author":"Roobol","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0095","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.eururo.2011.11.029","article-title":"Risk-based prostate cancer screening","volume":"61","author":"Zhu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0100","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/jnci\/djj410","article-title":"Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability","volume":"98","author":"Carter","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.09.033_bib0105","unstructured":"NCCN Guidelines. Prostate cancer early detection [v.2.2012]. National Comprehensive Cancer Network Web site. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf."},{"key":"10.1016\/j.eururo.2012.09.033_bib0110","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2008.18.1685","article-title":"Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer","volume":"27","author":"Vickers","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0115","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2012.09.033_bib0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","article-title":"Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer","volume":"147","author":"Benson","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0090-4295(00)00637-3","article-title":"Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging","volume":"56","author":"Catalona","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0130","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jama.1993.03510070082041","article-title":"Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges","volume":"270","author":"Oesterling","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2012.09.033_bib0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199608013350502","article-title":"Age-specific reference ranges for prostate-specific antigen in black men","volume":"335","author":"Morgan","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-6-19","article-title":"A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in G\u00f6teborg, Sweden","volume":"6","author":"Vickers","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0145","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","article-title":"Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication","volume":"28","author":"Vickers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-10-1003","article-title":"A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening","volume":"20","author":"Vickers","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2012.09.033_bib0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.juro.2008.04.015","article-title":"[-2]Proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network validation study","volume":"180","author":"Sokoll","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0160","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.juro.2009.12.056","article-title":"[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study","volume":"183","author":"Le","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2011.03.052","article-title":"Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng\/ml: results of a prospective study in a clinical setting","volume":"60","author":"Guazzoni","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0170","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2010.06.039","article-title":"Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test","volume":"58","author":"Roobol","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2010.09.036","article-title":"Prostate cancer detection in the \u201cgrey area\u201d of prostate-specific antigen below 10 ng\/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3","volume":"59","author":"Perdon\u00e0","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0180","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.juro.2011.01.075","article-title":"Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions","volume":"185","author":"de la Taille","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0185","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.cca.2012.04.017","article-title":"Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers","volume":"413","author":"Ferro","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.eururo.2012.09.033_bib0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","article-title":"EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease","volume":"59","author":"Heidenreich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0195","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1464-410X.2007.07309.x","article-title":"The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer","volume":"101","author":"Gosselaar","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0200","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.juro.2006.09.061","article-title":"The continuing importance of transrectal ultrasound identification of prostatic lesions","volume":"177","author":"Toi","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0205","doi-asserted-by":"crossref","first-page":"E237","DOI":"10.1111\/j.1464-410X.2011.10207.x","article-title":"Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort","volume":"108","author":"Trottier","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","article-title":"Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting","volume":"59","author":"Dickinson","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0215","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.juro.2006.08.007","article-title":"Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings","volume":"176","author":"Villers","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0220","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejrad.2009.08.007","article-title":"Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients","volume":"77","author":"Villeirs","year":"2011","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0225","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0230","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/djq265","article-title":"Effects of prostate-specific antigen testing on familial prostate cancer risk estimates","volume":"102","author":"Bratt","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.09.033_bib0235","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2796.2011.02504.x","article-title":"Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1)","volume":"272","author":"Thomas","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0245","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1464-410X.2006.06388.x","article-title":"African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram","volume":"98","author":"Yanke","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0250","doi-asserted-by":"crossref","unstructured":"Hemmerich JA, Ahmad FS, Meltzer DO, Dale W. African American men significantly underestimate their risk of having prostate cancer at the time of biopsy. Psychooncology. In press. http:\/\/dx.doi.org\/10.1002\/pon.2098.","DOI":"10.1002\/pon.2098"},{"key":"10.1016\/j.eururo.2012.09.033_bib0255","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2008.05.022","article-title":"The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review","volume":"54","author":"Schr\u00f6der","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0260","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.09.033_bib0265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1464-410X.2008.08127.x","article-title":"Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone","volume":"103","author":"Hernandez","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0270","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.juro.2009.08.056","article-title":"Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection","volume":"182","author":"Eyre","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0275","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ejca.2010.11.012","article-title":"Prediction of prostate cancer in unscreened men: external validation of a risk calculator","volume":"47","author":"van Vugt","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2012.09.033_bib0280","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.eururo.2010.06.023","article-title":"Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer Risk calculators: a performance comparison in a contemporary screened cohort","volume":"58","author":"Cavadas","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0285","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.ejca.2012.02.002","article-title":"Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort","volume":"48","author":"van Vugt","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2012.09.033_bib0290","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.juro.2006.09.025","article-title":"Development and external validation of an extended repeat biopsy nomogram","volume":"177","author":"Chun","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0295","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2007.10.6450","article-title":"Assessing individual risk for prostate cancer","volume":"25","author":"Nam","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0300","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.urology.2011.04.042","article-title":"Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information","volume":"78","author":"Zaytoun","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0305","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2008.06.043","article-title":"Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy","volume":"55","author":"Campos-Fernandes","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0310","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2011.04.069","article-title":"Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population","volume":"186","author":"Zaytoun","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0315","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2009.10.022","article-title":"Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen","volume":"183","author":"Hambrock","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0320","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.juro.2007.03.107","article-title":"Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score","volume":"178","author":"Mitterberger","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0325","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.juro.2010.05.026","article-title":"Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng\/ml or greater and 4.00 ng\/ml or less","volume":"184","author":"Aigner","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0330","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1442-2042.2010.02612.x","article-title":"Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data","volume":"17","author":"Miyagawa","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0335","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00330-008-1153-0","article-title":"Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings","volume":"19","author":"Lemaitre","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0340","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1442-2042.2007.01829.x","article-title":"Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study","volume":"14","author":"Sumura","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0345","unstructured":"Progensa PCA3 assay. US Food and Drug Administration Web site. www.fda.gov\/MedicalDevices\/ucm294907.htm."},{"key":"10.1016\/j.eururo.2012.09.033_bib0350","unstructured":"Premarket approval letter for the Progensa PCA3 assay. US Food and Drug Administration Web site. http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf10\/p100033a.pdf."},{"key":"10.1016\/j.eururo.2012.09.033_bib0355","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2007.11.038","article-title":"PCA3: a molecular urine assay for predicting prostate biopsy outcome","volume":"179","author":"Deras","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0360","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0365","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2009.03.029","article-title":"Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram","volume":"56","author":"Chun","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0370","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eururo.2010.06.038","article-title":"External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome","volume":"58","author":"Auprich","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0375","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.juro.2010.06.098","article-title":"PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial","volume":"184","author":"Aubin","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0380","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2011.08.003","article-title":"Contemporary role of prostate cancer antigen 3 in the management of prostate cancer","volume":"60","author":"Auprich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0385","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1464-410X.2010.09286.x","article-title":"The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?","volume":"106","author":"Ploussard","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0390","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1464-410X.2011.10584.x","article-title":"A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy","volume":"109","author":"Auprich","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0395","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0022-5347(05)00337-X","article-title":"Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care","volume":"175","author":"Epstein","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0400","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.eururo.2010.08.041","article-title":"Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature","volume":"58","author":"Chun","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0405","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00345-009-0413-1","article-title":"High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance","volume":"27","author":"Ploussard","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0410","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/PAS.0b013e3181c3ece9","article-title":"False-negative prostate needle biopsies: frequency, histopathology features, and follow-up","volume":"34","author":"Wolters","year":"2010","journal-title":"Am J Surg Pathos"},{"key":"10.1016\/j.eururo.2012.09.033_bib0415","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2559.2011.04007.x","article-title":"Precursors of prostate cancer","volume":"60","author":"Bostwick","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0420","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.juro.2009.04.016","article-title":"Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma","volume":"182","author":"Merrimen","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0425","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.urology.2010.07.519","article-title":"Long-term follow-up of men with isolated high-grade prostatic intra-epithelial neoplasia followed by serial delayed interval biopsy","volume":"77","author":"Godoy","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0430","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2010.1720","article-title":"Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis","volume":"304","author":"Hayes","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2012.09.033_bib0435","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.juro.2008.07.051","article-title":"Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance","volume":"180","author":"Berglund","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0440","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","article-title":"Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance","volume":"29","author":"Porten","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0445","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.eururo.2011.06.027","article-title":"Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program","volume":"61","author":"Bul","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0450","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2008.01.013","article-title":"PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance","volume":"179","author":"Nakanishi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0455","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2010.11.044","article-title":"Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance","volume":"59","author":"Ploussard","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0460","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.2011.10377.x","article-title":"The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance","volume":"109","author":"van Poppel","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0465","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.juro.2011.11.112","article-title":"Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study","volume":"187","author":"Margel","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0470","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-156-8-201204170-00009","article-title":"Active surveillance in men with localized prostate cancer: a systematic review","volume":"156","author":"Dahabreh","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0475","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.juro.2009.07.024","article-title":"Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails","volume":"182","author":"Duffield","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0480","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.juro.2011.06.055","article-title":"Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer","volume":"186","author":"Porten","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0485","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.juro.2009.08.044","article-title":"Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance","volume":"182","author":"Fujita","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0490","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0495","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eururo.2008.06.040","article-title":"Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer\u2014a review","volume":"54","author":"van den Bergh","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0500","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.juro.2009.10.003","article-title":"Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program","volume":"183","author":"Tosoian","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0505","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.urolonc.2011.02.014","article-title":"Clinical application of a 3D ultrasound-guided prostate biopsy system","volume":"29","author":"Natarajan","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0510","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.media.2011.01.008","article-title":"Prostate biopsy tracking with deformation estimation","volume":"16","author":"Baumann","year":"2012","journal-title":"Med Image Anal"},{"key":"10.1016\/j.eururo.2012.09.033_bib0515","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MOU.0b013e3283435118","article-title":"Innovations in prostate biopsy strategies for active surveillance and focal therapy","volume":"21","author":"Ukimura","year":"2011","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0520","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.urology.2007.09.029","article-title":"Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy","volume":"71","author":"Hara","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0525","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.pcan.4500985","article-title":"A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy","volume":"11","author":"Takenaka","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2012.09.033_bib0530","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.urology.2010.08.048","article-title":"Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate?","volume":"77","author":"Abdollah","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0535","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.juro.2012.05.006","article-title":"Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy","volume":"188","author":"Hossack","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0540","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jnci\/djm153","article-title":"Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence","volume":"99","author":"Haas","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2012.09.033_bib0545","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.urolonc.2006.03.003","article-title":"Improved prostate cancer detection with anterior apical prostate biopsies","volume":"24","author":"Wright","year":"2006","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.eururo.2012.09.033_bib0550","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1569-9056(02)00054-4","article-title":"Prostatic transrectal ultrasound (TRUS) guided biopsy schemes and TRUS prostatic lesion-guided biopsies","volume":"1","author":"Scattoni","year":"2002","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2012.09.033_bib0555","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/01.ju.0000173924.83392.cc","article-title":"The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume","volume":"174","author":"Remzi","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0560","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0022-5347(05)00957-2","article-title":"Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review","volume":"175","author":"Eichler","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0565","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0022-5347(05)00211-9","article-title":"Saturation technique does not improve cancer detection as an initial prostate biopsy strategy","volume":"175","author":"Jones","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0570","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2006.06.015","article-title":"Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy","volume":"51","author":"Kawakami","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2009.08.011","article-title":"Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy","volume":"57","author":"Scattoni","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0580","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO;2-D","article-title":"Detailed mapping of prostate carcinoma foci: biopsy strategy implications","volume":"89","author":"Chen","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2012.09.033_bib0585","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/pros.20859","article-title":"Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology","volume":"69","author":"Bouy\u00e9","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2012.09.033_bib0590","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/pros.20881","article-title":"Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology","volume":"69","author":"Haffner","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2012.09.033_bib0595","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0090-4295(98)00510-X","article-title":"Follow-up of atypical prostate needle biopsies suspicious for cancer","volume":"53","author":"Chan","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0600","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1464-410X.2006.06728.x","article-title":"The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer","volume":"99","author":"Schoenfield","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0605","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1200\/JCO.2008.20.3497","article-title":"Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management","volume":"27","author":"Onik","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0610","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.juro.2011.03.147","article-title":"Characterizing clinically significant prostate cancer using template prostate mapping biopsy","volume":"186","author":"Ahmed","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0615","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.07.036","article-title":"The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme","volume":"60","author":"Scattoni","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0620","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2011.08.042","article-title":"Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort","volume":"61","author":"Hambrock","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib125","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2012.01.047","article-title":"Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers","volume":"62","author":"Hoeks","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0630","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1464-410X.2011.10734.x","article-title":"Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning","volume":"110","author":"Simmons","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0635","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.juro.2012.01.063","article-title":"The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients","volume":"187","author":"Brock","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0640","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/j.1464-410X.2010.09735.x","article-title":"Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer","volume":"107","author":"Sano","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0645","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/PAS.0b013e3181c3ece9","article-title":"False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up","volume":"34","author":"Wolters","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0650","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2559.2011.03990.x","article-title":"Diagnosis of limited adenocarcinoma of the prostate","volume":"60","author":"Epstein","year":"2012","journal-title":"Histopathology"},{"issue":"Suppl 6","key":"10.1016\/j.eururo.2012.09.033_bib0655","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.urology.2007.07.037","article-title":"Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006","volume":"70","author":"Bostwick","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0660","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.juro.2007.08.072","article-title":"Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities","volume":"178","author":"Eggener","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib133","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2012.06.004","article-title":"Image-guided prostate biopsy using magnetic resonance imaging\u2013derived targets: a systematic review","volume":"63","author":"Moore","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0670","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.juro.2011.07.102","article-title":"A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion","volume":"186","author":"Hadaschik","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0675","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.juro.2011.05.078","article-title":"Magnetic resonance imaging\/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging","volume":"186","author":"Pinto","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0680","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.juro.2011.10.124","article-title":"Accuracy of 3D elastic registration system of prostate biopsy location by real-time 3D TRUS guidance with MR\/TRUS image fusion: pilot phantom study","volume":"187","author":"Ukimura","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0685","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.juro.2009.08.036","article-title":"Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy","volume":"182","author":"Lawrentschuk","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0690","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7863\/jum.2009.28.4.455","article-title":"Mapping of transrectal ultrasonographic prostate biopsies: quality control and learning curve assessment by image processing","volume":"28","author":"Mozer","year":"2009","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0695","doi-asserted-by":"crossref","unstructured":"Hori S, Fuge O, Trabucchi K, Donaldson P, McLoughlin J. Can a trained non-physician provider perform transrectal ultrasound-guided prostatic biopsies as effectively as an experienced urologist? BJU Int. In press. http:\/\/dx.doi.org\/10.1111\/j.1464-410X.2012.11294.x.","DOI":"10.1111\/j.1464-410X.2012.11294.x"},{"key":"10.1016\/j.eururo.2012.09.033_bib0700","doi-asserted-by":"crossref","first-page":"d7894","DOI":"10.1136\/bmj.d7894","article-title":"Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study","volume":"344","author":"Rosario","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2012.09.033_bib0705","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0022-5347(05)65851-X","article-title":"Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study","volume":"166","author":"Djavan","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0710","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1111\/j.1464-410X.2010.09712.x","article-title":"No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer","volume":"107","author":"Carlsson","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0715","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2007.09.005","article-title":"Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial","volume":"53","author":"Raber","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0720","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.juro.2008.10.002","article-title":"Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial","volume":"181","author":"Giannarini","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0725","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.juro.2009.11.043","article-title":"Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy","volume":"183","author":"Nam","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0730","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.eururo.2011.12.058","article-title":"Infectious complications and hospital admissions after prostate biopsy in a European randomized trial","volume":"61","author":"Loeb","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0735","first-page":"CD006576","article-title":"Antibiotic prophylaxis for transrectal prostate biopsy","author":"Zani","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2012.09.033_bib0740","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.urology.2010.12.067","article-title":"Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment","volume":"77","author":"Zaytoun","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2012.09.033_bib0745","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7863\/jum.2011.30.2.213","article-title":"Sepsis rates after ultrasound-guided prostate biopsy using a bowel preparation protocol in a community hospital","volume":"30","author":"Ruddick","year":"2011","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.eururo.2012.09.033_bib0750","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.juro.2008.01.068","article-title":"Best practice policy statement on urologic surgery antimicrobial prophylaxis","volume":"179","author":"Wolf","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0755","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2010.11.088","article-title":"Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy","volume":"185","author":"Liss","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0760","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1469-0691.2011.03638.x","article-title":"Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy\u2014should we reassess our practices for antibiotic prophylaxis?","volume":"18","author":"Steensels","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eururo.2012.09.033_bib0765","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.eururo.2012.04.044","article-title":"Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?","volume":"62","author":"Carignan","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0770","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.juro.2011.11.115","article-title":"Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care","volume":"187","author":"Taylor","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2012.09.033_bib0775","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1464-410X.2010.09715.x","article-title":"Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates","volume":"107","author":"Batura","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2012.09.033_bib0780","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1111\/j.1464-410X.2011.10768.x","article-title":"Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis","volume":"110","author":"Adibi","year":"2012","journal-title":"BJU Int"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812011013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283812011013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:11Z","timestamp":1759583051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283812011013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":156,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0302283812011013"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2012.09.033","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient Care","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2012.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}